Novavax reported $233.31M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Cassava Sciences USD 0 0 Dec/2024
Geron USD 121.92M 73K Sep/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
MannKind USD 119.91M 73.09M Sep/2025
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.31B 571M Dec/2025
Novartis USD 32.02B 615M Sep/2025
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.96B 3.11B Dec/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025